Cutaneous side-effects of kinase inhibitors and blocking antibodies.
about
Mechanisms underlying skin disorders induced by EGFR inhibitorsPrognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenibTen things you should know about protein kinases: IUPHAR Review 14Structural basis of selectivity and neutralizing activity of a TGFα/epiregulin specific antibodySunitinib in solid tumorsRASopathic skin eruptions during vemurafenib therapyNeutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptorMultikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management.Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects.Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitorsThe escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.Dermatologic toxicities in epidermal growth factor receptor and multikinase inhibitors.Randomized double-blind trial of prophylactic topical Evozac(®) Calming Skin Spray for gefitinib-associated acne-like eruption.Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma.Concurrent hand-foot skin reaction and hair depigmentation with sunitinib: report of a case and literature review of kinase inhibitors and blocking antibodiesAnticancer drug induced palmar plantar erythrodysesthesiaSkin care management in cancer patients: an evaluation of quality of life and tolerability.Diffuse hypopigmentation followed by hyperpigmentation in an african american woman with hemangiopericytoma treated with dasatinibRenal cell carcinoma and the use of sorafenib.A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature reviewEarly skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenibHFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome.Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implicationsFolliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review.CA-SSR1 Polymorphism in Intron 1 of the EGFR Gene in Patients with Malignant Tumors Who Develop Acneiform Rash Associated with the Use of Cetuximab.Targeting the MAPK-RAS-RAF signaling pathway in cancer therapyAlopecia in patients treated with molecularly targeted anticancer therapies.Effectiveness of medical supportive team for outpatients treated with sorafenib: a retrospective studyCutaneous pigmentation after photosensitivity induced by vandetanib therapyEmerging treatments for choroidal metastases.A comparison of epithelial-to-mesenchymal transition and re-epithelializationCetuximab in the treatment of metastatic colorectal cancer.Nail alterations as a surrogate marker for the efficacy of low-dose metronomic chemotherapy.Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Current role of antibody therapy in patients with metastatic colorectal cancer.Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care.Protein kinases as targets for cancer treatment.
P2860
Q26745689-245B0CE3-F33C-41DF-A665-A180AED7254BQ26765210-A875F981-7DFA-42A4-8BFD-51EEF82E1D41Q26849417-D1079426-307D-44D4-BF3E-041B7FA06C1EQ27727718-1680D411-632D-402C-8C77-77450504B861Q28245467-C56FBC7A-03B8-470B-AE5E-D8AEC9DC957EQ28488013-20EDC5E7-A71B-4DA8-94DB-2EFAA7FD962EQ28728031-9866AA76-311D-430A-9781-B876C5AECCD5Q30250106-5C6D1EA8-6234-422B-8E9A-D436F2C6ED6BQ33379941-A8BDEFDC-AAE9-4380-B2E3-E6D089E0F0A9Q33698419-894354F8-8652-439B-80D1-472377D0D37AQ33865354-07F05057-336E-4EBD-BFCB-226F1D5AC7D5Q33885559-C9364AEC-21C4-4D02-AC7D-159DDEFA5AF4Q33895537-26253B6D-5185-44F8-AB6B-5785B268BB5EQ33916002-46839D6E-1396-434F-92F0-E8D338D10742Q34591507-056BCA3B-5DB0-443E-AF0F-EFAD808FDF5DQ34618110-D70FD045-033A-4851-A23B-13C49EE34CAFQ34700294-3E6F7D45-4487-463C-BF14-87EEF47CBD03Q34910466-7F5EAA47-D245-4164-83E7-F048E65DCD43Q35166782-4E01DD36-7A9C-4BA9-A4C5-D7651E8A45A1Q35541916-6EA2E46D-E95A-49F3-ACF2-DF8C01CCDFC4Q35583678-FD6CB834-A681-4FEF-90CB-B3DB3AEAB5F6Q35584405-C24301CA-9EC8-4E25-8F36-C29265BBDC7EQ35584920-515C4DF6-31C3-4DD5-BBF6-1BA68CD99E5AQ35721081-ECE3A98C-6EDA-4DE0-8E32-43AB4E6CE380Q35759606-B7B92F2F-2283-4446-ABA0-111264DF55BEQ35913241-3F62E411-AD1C-4949-B9D8-5E0E3C730BAFQ36012730-FF2A3973-96F1-4C2C-A6FD-40193324EFADQ36278239-31598BE1-4147-4B30-8644-5BF2B035B5FEQ36316632-2FF65E56-1E75-40CA-BEF8-080F0893A568Q36368199-E2041CA6-620C-41BA-BDB5-10B31E1446E0Q36464597-6DAD40C8-D309-4B5F-AA8A-96342403797DQ36519807-1812AD64-02B6-499B-AD97-65BE35BBE807Q36678367-DAF28884-4418-4175-8A94-4F3DE3E9737CQ36717359-77C3BAE4-50F3-4597-81B5-14D70B1A1035Q36774289-B16068F7-EAD9-4E14-A949-0472689E7D09Q36781452-EC4939E4-0E91-4C03-8032-AF7F1ED2FBCAQ36822880-9C6AD613-217F-4D04-88BD-8A035B444109Q36832121-8DB65DD6-1195-4527-A9BF-03CE222E05F1Q36871021-1DEF62D2-6031-4051-AE3E-3082D15E53E3Q36918131-E5C2E678-528F-4915-A074-27692B7CD399
P2860
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
@ast
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
@en
type
label
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
@ast
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
@en
prefLabel
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
@ast
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
@en
P2093
P50
P1433
P1476
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
@en
P2093
Alain Spatz
Catherine Lhomme
David Malka
Janine Wechsler
Jean-Pierre Armand
Patricia Pautier
Valérie Boige
P304
P356
10.1016/S1470-2045(05)70243-6
P577
2005-07-01T00:00:00Z